Member Login

Publications

The International Prophylaxis Study Group (IPSG) is committed to advancing hemophilia research through peer-reviewed publications, clinical studies, and scientific presentations. Our work focuses on prophylaxis, pharmacokinetics, imaging, musculoskeletal health, and access to care, with the goal of improving treatment strategies and patient outcomes.

Below is a collection of IPSG-authored and collaborative publications, including studies on long-term prophylaxis, outcome measurement tools, and innovative treatment approaches. These resources serve as valuable references for clinicians, researchers, and healthcare policymakers worldwide.

May 10, 2018

Use of ultrasound for assessment of musculoskeletal disease in persons with hemophilia: Results of an International Prophylaxis Study Group (IPSG) survey.

Authors

Doria AS, von Drygalski A, Blanchette VS, Chang EY, Dover S, Fischer K, Sridhar G, Shyamkumar K, Querol F, Babyn P.

Citation

Haemophilia 2018; 24 (S5): 391, W- P- 085

May 10, 2018

Elevated HJHS Scores in healthy adult males without hemophilia

Authors

Feldman B, Zourikian N, Funk S, Tilak M, Lobet S, Manco-Johnson M, Srivastava A, Hilliard P, Tiseo L and St-Louis J

Citation

Haemophilia 2018; 24 (S5): 176, W- FPMED01- 002

April 24, 2017

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia

Authors

Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L; Factor Utilization Expert Working Group on behalf of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators.

Citation

Haemophilia 2017; 23 (5) : e444 - e447

April 21, 2017

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia

Authors

Carcao M, Avila L, Leissinger C, Blanchette VS, and Aledort LM on behalf of the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators

Citation

Haemophilia 2017; 23 (5):e447 - e450

March 30, 2017

Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates

Authors

Iorio A, K. Fischer BM, Blanchette V, Rangarajan S, Young G, Morfini M, for the Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG)

Citation

Thrombosis and Haemostasis 2017; 117 (6): 1023 - 1030

March 1, 2016

Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.

Authors

Berger K, Feldman BM, Wasserman J, Schramm W, Blanchette VS, Fischer K on behalf of the Outcome Measures Expert Working Group of the IPSG

Citation

Haematologica; March 2016 101: 266-268

December 7, 2015

Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors).

Authors

Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators

Citation

57th American Society of Hematology Meeting 2015.

December 3, 2015

Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)

Authors

Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.

Citation

Blood 2015; 126: 3535

June 20, 2015

Prophylaxis in adult patients with severe hemophilia A or B without inhibitors.

Authors

Carcao, M on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators.

1 2 3 4 5 … 8